← 返回

三项临床试验中血浆细胞因子水平对 IL12 治疗应答变化的分析

英文原题:Analysis of Changes in Plasma Cytokine Levels in Response to IL12 Therapy in Three Clinical Trials.

查看英文原题

Analysis of Changes in Plasma Cytokine Levels in Response to IL12 Therapy in Three Clinical Trials.

PubMed 2024/01/10(内容时间) Cancer Res Commun Q2 · IF 4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

IL12 刺激自然杀伤(NK)细胞和 T 细胞抗肿瘤活性的能力使其成为癌症免疫治疗的有吸引力的候选药物。我们的团队已证实 IL12 可增强 NK 细胞对抗体包被肿瘤细胞的反应,并开展了三项使用 IL12 联合 mAbs 的临床试验(OSU-9968、OSU-0167 和 OSU-11010)。为了更好地表征 IL12 诱导的免疫反应,我们测量了这些试验中 21 例具有有利和不利反应患者的血浆细胞因子水平。采用 t 检验和线性模型,通过检测基线和 IL12 给药后的水平,检验反应组内和组间的差异。总体分析显示,患者在 IL12 给药后 11 种细胞因子显著升高。然而,有几种细胞因子因反应不同而被 IL12 差异性诱导。完全/部分缓解患者的 GMCSF 显著升高,而疾病稳定患者的 IL10 显著升高、VEGF-C 显著降低。疾病进展患者的 CCL3、CCL4、IL18、TNF、CXCL10、CCL8、CCL2、IL6 和 IFN 显著升高。疾病进展患者 CCL3、CCL4 和 IL6 的升高显著高于临床获益患者,且在 IL12 治疗的前两个周期内最为显著。这项相关性初步研究确定了癌症患者给予 IL12 后循环细胞因子水平发生的变化,但本报告必须被视为探索性研究。其目的在于通过对具有相似特征且以统一方式接受 IL12 治疗的其他患者队列的分析,激发对该主题的进一步探究。意义:IL12 可激活免疫细胞并被用于治疗癌症。本研究以探索性方式检测了接受 IL12 联合单克隆抗体(mAbs)治疗的癌症患者循环细胞因子的谱型。这项相关性初步研究可作为进一步研究 IL12 对免疫细胞因子产生影响的依据。

展开英文摘要原文

UNLABELLED: The ability of IL12 to stimulate natural killer (NK) cell and T-cell antitumor activity makes it an attractive candidate for the immune therapy of cancer.

Our group has demonstrated that IL12 enhances the NK cell response to antibody-coated tumor cells and conducted three clinical trials utilizing IL12 with mAbs (OSU-9968, OSU-0167, and OSU-11010). To better characterize IL12-induced immunity, plasma cytokine levels were measured in 21 patients from these trials with favorable and unfavorable responses.

t-statistics and linear modeling were used to test for differences within and between response groups by examining levels at baseline and post-IL12 administration. Patients exhibited significant increases in 11 cytokines post-IL12 administration when analyzed collectively.

However, several cytokines were differentially induced by IL12 depending on response. GMCSF was significantly increased in complete/partially responding patients, while stable disease patients had significant increases in IL10 and decreases in VEGF-C. Patients who experienced progressive disease had significant increases in CCL3, CCL4, IL18, TNF , CXCL10, CCL8, CCL2, IL6, and IFN . The increases in CCL3, CCL4, and IL6 in progressive disease patients were significantly higher than in clinically benefitting patients and most prominent within the first two cycles of IL12 therapy.

This correlative pilot study has identified changes that occur in levels of circulating cytokines following IL12 administration to patients with cancer, but this report must be viewed as exploratory in nature. It is meant to spark further inquiry into the topic via the analysis of additional cohorts of patients with similar characteristics who have received IL12 in a uniform fashion.

SIGNIFICANCE: IL12 activates immune cells and is used to treat cancer. The profile of circulating cytokines was measured in an exploratory fashion in patients with cancer that received IL12 in combination with mAbs. This correlative pilot study could serve as the basis for additional studies of IL12 effects on the production of immune cytokines.

论文信息

作者
Schwarz E、Benner B、Yu L、Tounkara F、Carson WE 3rd
第一作者单位
Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University, Columbus, Ohio.United States
通讯作者单位
Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.United States
文献类型
临床试验 · 美国 NIH 资助研究
期刊
Cancer research communications2024 Jan 10
原文标识
PubMed 38108458 · DOI 10.1158/2767-9764.CRC-23-0122